Optimizing Pazopanib Exposure in RCC Patients

Inclusion Criteria: * signature of informed consent * age ≥ 18 years * histologically confirmed renal cell carcinoma with clear cell component and either locally progressed or metastasized * ECOG ≤ 2 * No previous systemic therapy for locally progressed or metastasized renal cell carcinoma (previous adjuvant or neo-adjuvant therapy is permitted) * Adequate organ function * Female patients with child-bearing potential with negative serum pregnancy test within 2 weeks prior to first dose of study medication and adequate contraception * Lactating females Exclusion Criteria: * Clinically suspected and known metastases of the central nervous system or carcinomatous meningitis except in asymptomatic patients with previously treated CNS-metastases and no necessity of steroids or anti-epileptic medication ≥ 6 months prior to start of the study medication * Clinically significant gastrointestinal conditions with risk of increase of gastrointestinal bleeding due to (but not limited to) * active peptic ulceration * known intraluminal metastases with risk of bleeding * chronic-inflammatory intestinal disease (like Morbus Crohn, ulcerative colitis) or another gastrointestinal disease with increased risk of perforation * abdominal fistulas in anamnesis * Clinically significant gastrointestinal conditions which can influence absorption of the IMP, among others (but not limited to) * malabsorption syndrome * resection of stomach or small bowel * Current uncontrolled infection * QTc corrected for heart frequency according to the Bazett formula * One or more of the following cardiovascular diseases within the last 6 months in the anamnesis: * cardiac angioplasty or coronary stent implantation * myocardial infarction * instable angina pectoris * coronary-arterial bypass surgery * symptomatic peripheral arterial occlusive disease * Heart failure NYHA III or IV * Poorly controlled high blood pressure * Cerebrovascular disease, including transitory ischemic attacks, pulmonary artery embolism or untreated deep vein thrombosis within 6 months of study inclusion * Previous major surgery or traumas within 28 days prior to start if study treatment or non-healing wound, fracture or ulcer * Clinical signs of active bleeding or bleeding diathesis * Known endobronchial lesions or lesions infiltrating the large lung arteries * Haemoptyses of \> 2.5 mL within 8 weeks prior to first intake of study medication * Any other severe and/or instable medical or psychiatric pre-existing or other condition influencing patient safety, consent capacity or compliance within the study * Incapacity or rejection to stop not allowed medication prior to first intake of study drug and pause for the duration of the trial * Treatment with one of the following anti-tumour therapies: * Radiation or tumour embolism within 14 days before first intake of study drug * Chemotherapy, Immunotherapy, biological therapy, study medication or hormonal therapy within 14 days or 5 half-lives of the respective substance (whichever is longer) before first intake of the study drug. Neo-adjuvant or adjuvant therapy must have been completed for at least 6 months. * Any present toxicity \> CTC 1° from prior anti-tumour therapy and/or toxicities worsening in severity except alopecia